alexa Evaluation of Clinico-Pathological Spectrum in Renal Allograft Biopsies at JIPMER | OMICS International
ISSN: 2472-1220
Journal of Kidney

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Evaluation of Clinico-Pathological Spectrum in Renal Allograft Biopsies at JIPMER

Puntambekar A1*, Parameswaran S2 and Nachiappa RG3

1Department of Internal Medicine (General Medicine), JIPMER, Puducherry, Tamil Nadu, India

2Department of Nephrology, Internal Medicine (General Medicine), JIPMER, Puducherry, Tamil Nadu, India

3Department of Pathology, JIPMER, Puducherry, Tamil Nadu, India

*Corresponding Author:
Anagha Puntambekar, MBBS
Department of Internal Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research
605006, Puducherry, Tamil Nadu, India
Tel: 0413 229 6562
E-mail: [email protected]

Received date: August 25, 2017; Accepted date: September 12, 2017; Published date: September 20, 2017

Citation: Puntambekar A, Parameswaran S, Nachiappa RG (2017) Evaluation of Clinico-Pathological Spectrum in Renal Allograft Biopsies at JIPMER. J Kidney 3:149. doi:10.4172/2472-1220.1000149

Copyright: © 2017 Puntambekar A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Kidney

Abstract

Background: Renal transplant patients in JIPMER undergo a systematic post-transplant follow-up in order to identify any new co-morbidity as well as detect abnormalities in graft function at the earliest and institute appropriate management. The renal allograft biopsy is one of the principal tools used by the nephrologists to diagnose any such episodes of graft dysfunction.

Objective: The aim of this study were to identify the chief causes of end stage renal disease and co-morbid conditions, to study the number of biopsies taken for each patient as a function of time and to assess the usefulness of an allograft biopsy.

Materials & Methods: A total of 120 renal transplants were carried out in JIPMER in a period of 5 years from March 2012 to March 2017. 78 patients who underwent renal allograft biopsies were included in the study, serial measurement of serum creatinine and change in dose of immunosuppressant were recorded and correlated with the biopsy findings.

Results: In exactly two-thirds of the patients (52) the cause for ESRD (End-Stage Renal Disease) could not be determined; in the remaining 26 secondary FSGS was the leading cause for ESRD. Systemic Hypertension (59%) was found to be the major co-morbidity in renal transplant patient, 82% patients underwent renal biopsy within the first 3 months after transplant and elevation in serum creatinine was the indication for most of the biopsies. A large fraction of the patients (64%) improved upon instituting appropriate treatment measures based on biopsy findings in correlation with other clinical and laboratory data.

Conclusion: Our findings suggest that for our setting renal allograft biopsy is the major modality of diagnosing the cause for derangement in graft function, especially in the early post-transplant period. Management course decided on the basis of biopsy findings results in improved patient outcome in a majority of cases.

Keywords

End-Stage Renal Disease; Allograft biopsy; Renal transplant

Introduction

Renal transplant patients undergo a vigilant follow-up in the posttransplant period. This enables a close monitoring of the renal allograft function. Immunosuppressant dose titration is critical in order to balance potential nephrotoxicity with the benefit of immunosuppression as well as prompt detection and treatment of various co-morbidities, often seen in these patients. Renal allograft biopsy is an important tool to study the status of the renal allograft [1]. It is the accepted gold standard for investigating episodes of graft dysfunction in the post-transplant period [2-5]. The major categories of graft dysfunction are acute or chronic rejection, CNI toxicity, infections or recurrence of primary renal disease [4,6]. Renal biopsy findings result in altering management decisions in approximately 40% of instances with presumptive diagnosis made on the basis of clinical and laboratory findings [4,5,7-9]. The follow-up of patients undergoing renal transplant over duration of 5 years was studied by a retrospective cohort method. The major co-morbidities affecting these patients were documented. The number of biopsies taken for a recipient after various time intervals was recorded along with the indication for each biopsy. In an effort to further analyze the usefulness of the renal allograft biopsy, the alteration in management course i.e. change in immunosuppressant dose done in accordance with the biopsy findings was correlated with improvement in graft function.

Objectives

The aims of this study were to:

1. Identify the spectrum of disease conditions causing morbidity in renal transplant recipients.

2. Determine the proportion of transplant recipients undergoing renal biopsy in first 3 months, 4-12 months and >12 months after transplantation.

3. Analyze the spectrum of clinical indications for initial graft biopsy and repeat graft biopsies.

4. Correlate the biopsy findings with clinical diagnosis.

Methodology

One hundred and twenty renal transplants were performed in JIPMER over duration of 5 years from March 2012 till March 2017. It is a retrospective observational study, all the patients who have undergone renal transplantation at JIPMER with pre-transplant work up and post-transplant follow-up at JIPMER were included in the study. Institute Scientific Advisory committee and Ethical committee approval was obtained for the study. The case records of these patients were studied from the Transplant Clinic in the Department of Nephrology, JIPMER. Biopsy records and other laboratory information of the transplant patients were retrieved from the Hospital information system. 78 of these patients were found to have undergone allograft biopsies for these patients the basic disease leading on to End-Stage Renal Disease (ESRD) was analyzed along with the co-morbidities developed in the post-transplant period. For a majority of the patients, the basic disease leading on to renal failure remained undetermined. Percentage analysis was done for End-Stage Renal Disease (ESRD) patients with an established renal pathology. The major co-morbidities were found to be systemic Hypertension (HTN), NODAT (New Onset Diabetes after Transplantation), anemia, urinary tract infections (UTI) and acute gastroenteritis. Again, percentage analysis was done to analyze the prevalence of each of these conditions. A total of 127 renal biopsies were studied in the post-transplant period. The details of date and indication for biopsy were collected from the case records. The proportion of patients undergoing biopsy after various time intervals after the transplant, i.e. first 3 months, 4-12 months and >12 months was calculated, the indications for the biopsies were also studied. The histopathology findings were classified as normal, immune-mediated rejection, CNI toxicity and infection. For each biopsy, the alteration in immunosuppressant dose, if any was correlated with an improvement in graft function measured as a fall in serum creatinine level in an attempt to correlate the histopathological diagnosis with the clinical diagnosis arrived at by the nephrologist.

Results

Out of the 120 patients who underwent renal transplant, 27 did not undergo post-transplant biopsies, for 12 patients follow-up records were not available and 3 of them had either inadequate or postmortem biopsies. All the biopsies were performed under ultrasound guidance and 16 gauge needles was the one that was commonly used. Blood pressure was brought under control as much as possible before the biopsy. In high risk patients, 18 gauge needles were used to perform the renal biopsy in our centre. No patient had any major complications secondary to renal biopsy in the post-transplant period except five patients who had transient hematuria. In two-thirds of these patients (52 of 78), the cause for ESRD remained undetermined. Of those with an established basic disease secondary FSGS was the leading cause of renal failure (6 patients), followed by IgA nephropathy (5 patients) and diabetic nephropathy (4 patients). The other causes included post-partum renal cortical necrosis, adult dominant polycystic kidney disease (ADPKD), congenital obstructive uropathy (Posterior urethral valve and pelvi-ureteric junction obstruction), hypertensive nephrosclerosis, renal stone disease, Ectopic single contracted kidney, Henoch Schonlein purpura nephritis and chronic interstitial nephritis (Table 1 and Figure 1).

S. No. Cause Number of patients
1 Undetermined 52
2 Secondary FSGS 6
3 IgA nephropathy 5
4 Diabetic nephropathy 4
5 Post-partum renal cortical necrosis 2
6 ADPKD 2
7 Congenital obstructive uropathy 2
8 Hypertensive nephrosclerosis 1
9 Renal stone disease 1
10 Ectopic single contracted kidney 1
11 HSP nephritis 1
12 Chronic interstitial nephritis 1
  Total 78

Table 1: Cause for ESRD in renal transplant recipients.

kidney-renal-transplant-recipients

Figure 1: Causes for ESRD in renal transplant recipients.

Overall, 59% of the patients had systemic hypertension as an associated co-morbidity, 42.3% patients developed New Onset Diabetes after Transplantation (NODAT), 30.8% patients had associated anemia, 19.2% patients had episodes of UTI and 9% patients had episodes of acute gastroenteritis. Hypothyroidism was seen to be associated with 7.7% of patients (Table 2).

S. No. Co-morbidity % of patients
1 Systemic Hypertension 59
2 NODAT 42.3
3 Anemia 30.8
4 UTI 19.2
5 Acute gastroenteritis 9
6 Hypothyroidism 7.7

Table 2: Associated co-morbidities in renal transplant recipients.

During the first three months after transplant 82% patients had episodes of graft dysfunction necessitating a biopsy, repeat biopsies were required for 41% patients. In the time period between 4-12 months, 48.7% of the patients underwent biopsies and 19.2% patients underwent repeat biopsies. Only 28.2% of patients required a biopsy after 1 year while 9% of patients required repeat biopsies in this duration (Table 3).

S. No. Time period % of patients undergoing biopsy % of patients undergoing repeat biopsy
1 First 3 months 82 41
2 4 to 12 months 48.7 19.2
3 More than 12 months 28.2 9

Table 3: Biopsies required in various time periods after transplant.

Analysis of the clinical indications for the biopsies revealed that 93.8% of the biopsies had been taken on the basis of an elevated serum creatinine level, 4.7% of the biopsies were indicated because of a delayed or slow graft function diagnosed due to inadequate urine output (Table 4).

S. No. Indication No. of biopsies % of biopsies
1 Elevated serum creatinine 119 93.8
2 Delayed graft function 6 4.7
3 Persistently delayed graft function 1 0.8
4 Unexplained proteinuria 1 0.8

Table 4: Indications for biopsies in post-transplant period.

Upon analyzing the histopathological findings, it was found that 34.6% of the biopsies had normal light microscopy and no evidence of immunoglobulin deposits on immunofluorescence. In 27.6% biopsies, immune mediated rejection (both early and late cellular and antibody mediated rejection) was found 13.4% biopsies suggested CNI toxicity as the diagnosis while in 24.4% of the biopsies infection was found to be the cause of graft dysfunction (Figure 2).

kidney-renal-post-transplant

Figure 2: Histopathological findings in post-transplant.

On correlating the histopathological diagnosis with the change in immunosuppressant dose, it was found that for 59.1% of patients with a histopathologically normal biopsy, no change in immunosuppressant dose was made for 25.7% of patients with biopsy findings suspicious of rejection an increment in immunosuppressant dose was made.

In 82.4% of patients with biopsy suggestive of CNI toxicity, a reduction in immunosuppressant dose was made, in 64.2% of biopsies, a reduction in serum creatinine was seen with improvement in renal function, while in 15.4% serum creatinine remained persistently elevated. An increase in serum creatinine was seen in 20.3% of the patients after therapeutic intervention based on biopsy findings (Tables 5 and 6).

Biopsy finding No change % IS dose increased % IS dose decreased % Total %
Normal 26 59.1 7 15.9 11 25 44 100
Rejection 17 48.6 9 25.7 9 25.7 35 100
CNI toxicity 1 5.9 2 11.8 14 82.4 17 100
Infection 22 71 3 9.7 6 19.4 31 100
Total 66 52 21 16.5 40 31.5 127  

Table 5: Correlation of biopsy finding with change in immunosuppressant (IS) dose.

S. No. Change in creatinine  No. of biopsies  (Total 123) % of biopsies
1 Decrease 79 64.2
2 Increase 25 20.3
3 No change 19 15.4

Table 6: Change in serum creatinine after biopsy on follow-up.

Only 4 of the 120 patients who underwent renal transplants had failure of the graft and 2 of the patients had repeat transplantation, there was recurrence of native disease in 2 of the recipients. 11 patients died after renal transplantation and sepsis was the cause in 55% of the patients.

Discussion

Renal biopsy is the gold standard in the assessment of deterioration of renal function of both native and allograft kidney. The disease activity, severity and chronicity and the nature of the disease process viz., rejection, recurrence of the native disease, infections, drug toxicities or occurrence of de-novo new pathology can be identified by findings in the renal biopsy [10]. The most common indications for renal biopsy in the post-transplant setting were renal function deterioration or proteinuria. In our study, the indication for 94% of the biopsies was elevated serum creatinine and reduced estimated glomerular filtration rate (eGFR). We had only one patient who had a renal biopsy secondary to unexplained proteinuria. Other major indications in our centre were delayed and slow graft function or persistent delayed graft function (Table 7).

S.No Reference study Total biopsies studied Common indications
1 Tsai et al. [10] 1563 Elevation of serum creatinine and unexplained proteinuria
2 Our study 127 Elevation of serum creatinine (94%). Uncommon indications - delayed and slow graft function, persistently delayed graft function and unexplained proteinuria

Table 7: Indication for renal biopsy.

Renal biopsy is relatively a safe procedure and in our centre, we report only minor complications accounting of 4% of the patients. This is comparable to the results in other centers. None of our patients needed blood transfusion, admission or surgical intervention due to post-renal biopsy complications (Table 8) [11].

S.No Reference study Total biopsies studied Common Complications reported
1 Tsai et al. [10] 1563                                                     Major complications - 2.8%                     Minor complications - 10%
Arteriovnous fistula, Hemoglobin decline, gross hematuria, and hematoma
2                                                               Canelas et al. [11] (2014) 390 Major complications requiring transfusion, embolisation, surgical intervention or death - 5.9%
  Minor complications - hematoma, hematuria and fever - 6.9%
3 Our study 127 No major complications Minor complication - Transient hematuria - 4%

Table 8: Complications from renal biopsy.

In our study, the incidence of biopsy proven acute rejection in both early (<3 months) and late (>3 months) after the transplant accounted for 27.6% of the patients. This was similar to the 23% rejection reported in the 2012 OPTN/UNOS records and Koo et al. (Table 9) [12-14]. In our study, 31 patients had biopsy proven evidence of infection including infections with BK virus, Cytomegalovirus and acute pyelonephritis (both early and late defined as within 6 months and after 6 months respectively). This accounted for 24.4% of posttransplant biopsies. 79% of the patients showed recovery from infection and improvement in renal function after initiation of appropriate treatment with biopsy findings. Majority of the patients required decrease in dose of immunosuppression with administration of antibiotics. In few patients, the dose of immunosuppression was not decreased due to concomitant rejection, 2 of the patients with biopsy proven acute graft pyelonephritis showed persistent graft dysfunction in spite of appropriate treatment. In our study, 5% of transplant patients (6 of the total 120) died due to sepsis. However, the total mortality in transplanted patients in our setting was 10% and 4 of the 120 patients (3%) had graft failure of which two of the patients underwent repeat transplantation. Our findings are better than the results described by Varma et al. who described mortality rate of 15% and almost most of the patients in their series, did not recover baseline renal function [15]. 28% of their patients had bacteremia at presentation, this is explained by the heterogeneous policies in definition of acute graft pyelonephritis and post-transplant management protocols. However, our results are comparable with Kayler et al. [16]. The major challenge in the interpretation of biopsy findings particularly in the context of viral infections is the concomitant interstitial and tubular infiltration by lymphocytes, mimicking cellular rejection. Thus correct interpretation of subtle morphological findings and good clinico-pathological correlation is extremely critical in appropriate management of these patients.

S.No Reference study Total transplant patients studied Incidence of Biopsy proven acute rejection (both Early and late acute rejection)
1 Koo et al. [12] 709 30%(198)
2 Garcia et al. [13] 175 14.3%(25)
3 Our study 35 27.60%
4 OPTN/UNOS 2012 [14] Guidelines 25%

Table 9: Incidence of acute rejection.

The strength of our study is availability of clinical, laboratory, drug details and biopsy records of all the patients with good follow-up of over 1 year in majority of the patients. However, our study is limited by the retrospective nature of the study, small sample size and difficulties in analyzing the different treatment strategies which vary according to the clinical manifestations and laboratory back-up available at the given time.

Summary

Our study highlights that most (2/3rd) of the patients requiring transplantation in our setting do not have the diagnosis for the cause of ESRD. In the subset of patients with known cause for ESRD, focal segmental glomerulosclerosis followed by IgA nephropathy and diabetic nephropathy were the common indications for renal transplant. Renal biopsy was the major diagnostic modality in the early post-transplant period (<3 months) and the number of repeat biopsies significantly decreased after 1 year of transplantation. The major indication for renal biopsy in our center was elevated serum creatinine with abnormal renal function, the other common indications were delayed graft function, slow graft function and proteinuria.

In our center, 25.75% of the transplant recipients had biopsy proven evidence of rejection while 33% of the patients had infections due to post-transplant immunosuppression. Most of the transplant biopsies (39.4%) of the patients had normal light microscopy while 13.4% patients had calcineurin inhibitor toxicity. Majority of the patients (65%) responded to appropriate treatment measures initiated based on biopsy findings in correlation with other clinical and laboratory data, while 15% had persistent renal dysfunction, 20% of the patients had deterioration in renal function.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • International Conference on Medical and Health Science
    August 24-25, 2018 Tokyo, Japan
  • 11th International Conference on Clinical and Medical Case Reports
    October 22-23, 2018 Istanbul, Turkey

Article Usage

  • Total views: 486
  • [From(publication date):
    September-2017 - Jul 17, 2018]
  • Breakdown by view type
  • HTML page views : 439
  • PDF downloads : 47
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7